Edition:
India

Champions Oncology Inc (CSBR.OQ)

CSBR.OQ on NASDAQ Stock Exchange Capital Market

7.12USD
22 Jun 2018
Change (% chg)

$0.36 (+5.33%)
Prev Close
$6.76
Open
$6.77
Day's High
$7.12
Day's Low
$6.74
Volume
23,139
Avg. Vol
5,474
52-wk High
$7.26
52-wk Low
$2.44

Latest Key Developments (Source: Significant Developments)

Champions Oncology Partners With Puma Biotechnology And Nsabp Foundation On Metastatic Breast And Colon Cancer Co-Clinical Pdx Studies
Monday, 18 Jun 2018 

Champions Biotechnology Inc ::CHAMPIONS ONCOLOGY PARTNERS WITH PUMA BIOTECHNOLOGY AND NSABP FOUNDATION ON METASTATIC BREAST AND COLON CANCER CO-CLINICAL PDX STUDIES.CHAMPIONS BIOTECHNOLOGY - FIRST TRIAL IS PHASE II STUDY OF TRASTUZUMAB EMTANSINE WITH NERATINIB IN WOMEN WITH METASTATIC HER2-POSITIVE BREAST CANCER.CHAMPIONS BIOTECHNOLOGY- SECOND TRIAL IS FOR NERATINIB+TRASTUZUMAB/NERATINIB +CETUXIMAB IN PATIENTS WITH "QUADRUPLE WILD-TYPE" METASTATIC COLORECTAL CANCER.  Full Article

Champions Oncology Reports Record Quarterly Revenue Of $5.2 Million
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Champions Biotechnology Inc ::CHAMPIONS ONCOLOGY REPORTS RECORD QUARTERLY REVENUE OF $5.2 MILLION.Q2 REVENUE ROSE 16.7 PERCENT TO $5.2 MILLION.SEES FY 2018 REVENUE UP AT LEAST 20 PERCENT.CHAMPIONS BIOTECHNOLOGY INC - REITERATED EXPECTATIONS FOR FISCAL YEAR 2018 REVENUE GROWTH OF AT LEAST 20% OVER FISCAL YEAR 2017.CHAMPIONS BIOTECHNOLOGY INC - QTRLY LOSS PER SHARE $0.01.CHAMPIONS BIOTECHNOLOGY - REITERATES POSITION THAT "IT DOES NOT CURRENTLY INTEND TO RAISE CAPITAL IN THE EQUITY MARKET".  Full Article

Champions Oncology posts Q3 adj. loss per share $0.11
Friday, 17 Mar 2017 

Champions Biotechnology Inc : Champions Oncology reports 40 pct revenue growth . Q3 revenue rose 39.7 percent to $3.6 million . For Q3 of fiscal 2017, champions reported a loss from operations of $1.4 million . Qtrly non-GAAP loss per share $ 0.11 . Qtrly GAAP loss per share $0.13 . Qtrly non-GAAP loss per share $0.11 .Champions Biotechnology Inc - company ended quarter with $3.5 million of cash and cash equivalents on balance sheet.  Full Article